Maria-Victoria Mateos

2 weeks ago | onclive.com | Maria-Victoria Mateos

CommentaryVideoApril 9, 2025Author(s):María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes. "The next step is, of course, to move [cilta-cel] into the first line of therapy.

3 weeks ago | onclive.com | Maria-Victoria Mateos

CommentaryVideoApril 1, 2025Author(s):María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

2 months ago | nature.com | Katja Weisel |Maria-Victoria Mateos |Meletios Athanasios Dimopoulos

AbstractPatients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have received at least 4 prior lines of therapy, based on response rates observed in DREAMM-1/DREAMM-2.

Dec 4, 2024 | nature.com | S. Vincent Rajkumar |Maria-Victoria Mateos

AbstractThis study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, International Myeloma Working Group (IMWG) 2020, and AQUILA trial risk criteria.

Oct 20, 2024 | nature.com | Nizar Bahlis |Luciano Costa |Maria-Victoria Mateos |Ajay K. Nooka |Aurore Perrot |Alfred Garfall | +1 more

Dear Editor,The risk of infection in patients with multiple myeloma (MM) is high, particularly for those with relapsed/refractory MM (RRMM), who typically exhibit substantial immune dysfunction due to multiple prior therapies as well as MM itself [1, 2]. The recent COVID-19 pandemic had an impact on patients with MM compared with non-MM patients, including a higher risk of infection, a higher excess mortality rate, and decreased survival in 2020 compared with 2019 [3].